Anergis
Latest round
- Series B
Last raised
- Dec 2014
Total raised
- $35M
Investors
- 5
About Anergis
Founded in 2001, Anergis SA operates in the biotechnology sector, focusing on allergy immunotherapy.ch specializes in innovative solutions within the biotechnology sector, focusing primarily on the development and manufacturing of allergy immunotherapy products. Their core offerings revolve around advanced immunotherapy treatments designed to desensitize patients to specific allergens, effectively alleviating allergy symptoms and enhancing quality of life. These products are typically intended for individuals suffering from common allergens, which can range from pollen to pet dander, and cater to a diverse client base that includes healthcare providers, allergists, and patients across several geographical markets in Europe and North America. The company's products aim to address the rising prevalence of allergic conditions and provide efficient therapeutic alternatives, promoting patient compliance through their user-friendly administration methods.ch generates revenue primarily through a B2B model, engaging directly with healthcare institutions and practitioners who utilize their allergy immunotherapy products. The transaction structure is characterized by bulk purchasing agreements and potential subscription models for ongoing product supply and support services. Their flagship products are priced competitively within the allergy treatment market, reflecting their efficacy and the value they provide to healthcare providers and patients alike. Revenue is derived from both one-time sales and recurring orders, as healthcare providers restock their inventories based on patient needs and treatment regimens. The company aims to expand its product line of allergy immunotherapy products, targeting a launch within the next 18 months.
Who invested in Anergis
5 investors across 2 rounds
See all investors in Anergis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Anergis
Who invested in Anergis?
Anergis has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Anergis raised?
Anergis has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Anergis last raise money?
Anergis's most recent round on record is a Series B, in Dec 2014.
What does Anergis do?
Founded in 2001, Anergis SA operates in the biotechnology sector, focusing on allergy immunotherapy.
Where is Anergis headquartered?
Anergis is headquartered in Switzerland.
Which VCs invest in companies like Anergis?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Anergis's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Anergis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.